P-ISSN 2587-2400 | E-ISSN 2587-196X
Ejmo Kapak
EJMO Volume : 5 Issue : 4 Year : 2021
EJMO. 2021; 5(4): 361-367 | DOI: 10.14744/ejmo.2021.47478

Sarcomatoid Transformation of Cromophobe Renal Cell Carcinoma: An Unusual Pathology. Our Experience, Definition of Therapeutic Guidelines and Review of Literature

Irene De La Parra1, Álvaro Serrano1, Roser Vives1, Juan Hermida1, Luis Ignacio Diez-Valladares2, Jerónimo Barrera3, José Antonio Cortés4, Pilar González-Peramato5, Ángel Gómez1, Jesús Moreno1
1Department of Urology, Health Research Institute, Clínico San Carlos Hospital, Complutense University, Madrid, Spain, 2Department of General Surgery, Clínico San Carlos Hospital, Madrid, Spain, 3Department of Radiology, Clínico San Carlos Hospital, Madrid, Spain, 4Department of Pathology, Clínico San Carlos Hospital, Madrid, Spain, 5Department of Pathology, University Hospital La Paz, Autónoma University, Madrid, Spain,

Chromophobe renal cell carcinoma (ChRCC) accounts for 4-6% of RCC1. Most of ChRCC have good prognosis, but sarcomatoid transformation implies poor prognosis factor2. Although sarcomatoid RCC was initially described as an own histological entity3, despite the fact that its transformation mechanism is not known, it is nowadays recognized that this histology represents a transformation or dedifferentiation of a high-grade malignant neoplasia originating from any other histological subtype of RCC2. ChRCC with sarcomatoid differentiation is very rare, with a few reported cases and there is no consensus about the treatment of patients affected by this variant of RCC in the guidelines. Therefore, we consider appropriate to present these two cases and review the literature, focusing on the incidence and the current therapeutic options. Keywords: Renal cell carcinoma, Chromophobe renal cell carcinoma, Sarcomatoid transformation


Cite This Article

De La Parra I, Serrano Á, Vives R, Hermida J, Diez-Valladares L, Barrera J, et al. Sarcomatoid Transformation of Cromophobe Renal Cell Carcinoma: An Unusual Pathology. Our Experience, Definition of Therapeutic Guidelines and Review of Literature. EJMO. 2021; 5(4): 361-367

Corresponding Author: Irene De La Parra

Full Text PDF PDF Download
EJMO & EJMO